Previous Close | 0.0267 |
Open | 0.0251 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0251 - 0.0329 |
52 Week Range | 0.0200 - 0.0700 |
Volume | |
Avg. Volume | 240,143 |
Market Cap | 10.46M |
Beta (5Y Monthly) | 0.13 |
PE Ratio (TTM) | 4.71 |
EPS (TTM) | 0.0070 |
Earnings Date | Aug 28, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for GBLX
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes Featured Image for GB Sciences Featured Image for GB Sciences LAS VEGAS, May 12, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, discusses the current a
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, May 05, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, spoke
Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome. COVID Research COVID Research LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will consult on Gb Sciences' go-to-market strategy for its COVID-19-rel